Ocular Therapeutix, Inc.OCULNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank77
3Y CAGR+100.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+100.6%/yr
vs -23.3%/yr prior
Acceleration
+123.9pp
Accelerating
Percentile
P77
Within normal range
vs 3Y Ago
8.1x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 54.42% |
| 2024 | 109.05% |
| 2023 | 14.20% |
| 2022 | 6.75% |
| 2021 | 74.54% |
| 2020 | -30.17% |
| 2019 | 11.31% |
| 2018 | 19.54% |
| 2017 | 14.10% |
| 2016 | 1.71% |